These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38729564)

  • 1. Impact of cholecystectomy on the gut-liver axis and metabolic disorders.
    Amaral Raposo M; Sousa Oliveira E; Dos Santos A; Guadagnini D; El Mourabit H; Housset C; Lemoinne S; Abdalla Saad MJ
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102370. PubMed ID: 38729564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A High-Fat, High-Cholesterol Diet Promotes Intestinal Inflammation by Exacerbating Gut Microbiome Dysbiosis and Bile Acid Disorders in Cholecystectomy.
    Xu F; Yu Z; Liu Y; Du T; Yu L; Tian F; Chen W; Zhai Q
    Nutrients; 2023 Sep; 15(17):. PubMed ID: 37686860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. You Are What You Eat-The Relationship between Diet, Microbiota, and Metabolic Disorders-A Review.
    Moszak M; Szulińska M; Bogdański P
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by
    Ye X; Huang D; Dong Z; Wang X; Ning M; Xia J; Shen S; Wu S; Shi Y; Wang J; Wan X
    Microbiol Spectr; 2022 Oct; 10(5):e0051822. PubMed ID: 36036629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid metabolism and signaling, the microbiota, and metabolic disease.
    Cai J; Rimal B; Jiang C; Chiang JYL; Patterson AD
    Pharmacol Ther; 2022 Sep; 237():108238. PubMed ID: 35792223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bile-gut axis and metabolic consequences of cholecystectomy.
    Lange AH; Pedersen MG; Ellegaard AM; Nerild HH; Brønden A; Sonne DP; Knop FK
    Eur J Endocrinol; 2024 Mar; 190(4):R1-R9. PubMed ID: 38551177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of apolipoprotein H downregulation on lipid metabolism, fatty liver disease, and gut microbiota dysbiosis.
    Liu Y; Zhao Y; Liu Q; Li B; Daniel PV; Chen B; Wu Z
    J Lipid Res; 2024 Jan; 65(1):100483. PubMed ID: 38101620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acids as regulatory molecules and potential targets in metabolic diseases.
    Xie AJ; Mai CT; Zhu YZ; Liu XC; Xie Y
    Life Sci; 2021 Dec; 287():120152. PubMed ID: 34793769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis.
    Qin D; Pan P; Lyu B; Chen W; Gao Y
    Biomed Pharmacother; 2024 Aug; 177():116942. PubMed ID: 38889641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile Acid Metabolism in Liver Pathobiology.
    Chiang JYL; Ferrell JM
    Gene Expr; 2018 May; 18(2):71-87. PubMed ID: 29325602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of the Gut Microbiota in Bile Acid Metabolism.
    Ramírez-Pérez O; Cruz-Ramón V; Chinchilla-López P; Méndez-Sánchez N
    Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s15-s20. PubMed ID: 29080339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystectomy Significantly Alters Gut Microbiota Homeostasis and Metabolic Profiles: A Cross-Sectional Study.
    Xu F; Chen R; Zhang C; Wang H; Ding Z; Yu L; Tian F; Chen W; Zhou Y; Zhai Q
    Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mining Gut Microbiota From Bariatric Surgery for MAFLD.
    Wu WK; Chen YH; Lee PC; Yang PJ; Chang CC; Liu KL; Hsu CC; Huang CC; Chuang HL; Sheen LY; Liu CJ; Wu MS
    Front Endocrinol (Lausanne); 2021; 12():612946. PubMed ID: 33897617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digestive dynamics: Unveiling interplay between the gut microbiota and the liver in macronutrient metabolism and hepatic metabolic health.
    Kandalgaonkar MR; Kumar V; Vijay-Kumar M
    Physiol Rep; 2024 Jun; 12(12):e16114. PubMed ID: 38886098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease.
    Long Q; Luo F; Li B; Li Z; Guo Z; Chen Z; Wu W; Hu M
    Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38407327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gut microbiota-bile acid axis in cholestatic liver disease.
    Sun D; Xie C; Zhao Y; Liao J; Li S; Zhang Y; Wang D; Hua K; Gu Y; Du J; Huang G; Huang J
    Mol Med; 2024 Jul; 30(1):104. PubMed ID: 39030473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gut microbiota-bile acid axis: A potential therapeutic target for liver fibrosis.
    Zhang YL; Li ZJ; Gou HZ; Song XJ; Zhang L
    Front Cell Infect Microbiol; 2022; 12():945368. PubMed ID: 36189347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
    Chen L-p; Zhang L-f; Liu S; Hua H; Zhang L; Liu B-c; Wang R-r
    Microbiol Spectr; 2024 Jun; 12(6):e0197923. PubMed ID: 38647315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion.
    Hu H; Shao W; Liu Q; Liu N; Wang Q; Xu J; Zhang X; Weng Z; Lu Q; Jiao L; Chen C; Sun H; Jiang Z; Zhang X; Gu A
    Nat Commun; 2022 Jan; 13(1):252. PubMed ID: 35017486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.